de Stanchina, Elisa

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.

Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 504

The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis

Chang, Q., Bournazou, E., Sansone, P., Berishaj, M., Gao, S. P., Daly, L., Wels, J., Theilen, T., Granitto, S., Zhang, X., et al. (2013) · Neoplasia

Cytokine Signaling Pathways and InteractionsCancer Cells and Metastasis

Cited by 494

Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia

Shih, A. H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. (2015) · Cancer Cell

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 236

Antitumorigenic potential of STAT3 alternative splicing modulation

Zammarchi, F., de Stanchina, E., Bournazou, E., Supakorndej, T., Martires, K., Riedel, E., Corben, A. D., Bromberg, J. F., & Cartegni, L. (2011) · Proceedings of the National Academy of Sciences

Cytokine Signaling Pathways and InteractionsRNA Research and Splicing

Cited by 176

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 150

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

Luke, J. J., D'Adamo, D. R., Dickson, M. A., Keohan, M. L., Carvajal, R. D., Maki, R. G., de Stanchina, E., Musi, E., Singer, S., & Schwartz, G. K. (2012) · Clinical Cancer Research

Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 95

Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding

Chen, W., Gupta, A., Mai, N., Nag, S., Lau, J. S., Singh, S., Chodera, J. D., Liu, B., de Stanchina, E., Pareja, F., et al. (2026) · Cancer Discovery

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 50

Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth

Rothman, J. H., Surriga, O., de Stanchina, E., Vasudeva, S. D., & Schwartz, G. K. (2017) · Cancer Gene Therapy

RNA Interference and Gene DeliveryMelanoma and MAPK Pathways

Cited by 4

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236

Pfeil, A. J., Zhang, T., Cheng, R., Mattar, M. S., Gomez Marti, J. L., Gili, L., Lai, R., Khodos, I., Master, R. P., Dix, J.-M., et al. (2025) · Clinical Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 3

Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023)

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 0